Processa Accounts Payable from 2010 to 2026

PCSA Stock  USD 2.22  0.07  3.06%   
Processa Pharmaceuticals' Accounts Payable is increasing over the years with slightly volatile fluctuation. Overall, Accounts Payable is expected to go to about 1.1 M this year. Accounts Payable is the amount Processa Pharmaceuticals owes to suppliers or vendors for products or services received but not yet paid for. It represents Processa Pharmaceuticals' short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2012-09-30
Previous Quarter
785.8 K
Current Value
727.2 K
Quarterly Volatility
223.6 K
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Processa Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Processa Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 99.5 K, Selling General Administrative of 3 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 198, Dividend Yield of 0.0 or PTB Ratio of 1.74. Processa financial statements analysis is a perfect complement when working with Processa Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Processa Stock
Check out the analysis of Processa Pharmaceuticals Correlation against competitors.
For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.
Analyzing Processa Pharmaceuticals's Accounts Payable over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Accounts Payable has evolved provides context for assessing Processa Pharmaceuticals's current valuation and future prospects.

Latest Processa Pharmaceuticals' Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Processa Pharmaceuticals over the last few years. An accounting item on the balance sheet that represents Processa Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Processa Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Processa Pharmaceuticals' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Processa Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

Processa Accounts Payable Regression Statistics

Arithmetic Mean304,431
Geometric Mean167,031
Coefficient Of Variation112.54
Mean Deviation245,980
Median159,249
Standard Deviation342,594
Sample Variance117.4B
Range1.1M
R-Value0.80
Mean Square Error44.8B
R-Squared0.64
Significance0.0001
Slope54,383
Total Sum of Squares1.9T

Processa Accounts Payable History

20261.1 M
2025M
2024880.9 K
2023311.6 K
2022327.5 K
2021218.9 K
2020320.7 K

About Processa Pharmaceuticals Financial Statements

Processa Pharmaceuticals stakeholders use historical fundamental indicators, such as Processa Pharmaceuticals' Accounts Payable, to determine how well the company is positioned to perform in the future. Although Processa Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Processa Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Processa Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Processa Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Accounts PayableM1.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Processa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Processa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Processa Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Processa Pharmaceuticals Stock:
Check out the analysis of Processa Pharmaceuticals Correlation against competitors.
For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Processa Pharmaceuticals. Anticipated expansion of Processa directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Processa Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(28.75)
Return On Assets
(1.30)
Return On Equity
(2.71)
Investors evaluate Processa Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Processa Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Processa Pharmaceuticals' market price to deviate significantly from intrinsic value.
It's important to distinguish between Processa Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Processa Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Processa Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.